文献库，生知库 | 链接生命科学的每一步

Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development

利用PBMC人源化小鼠的定量系统药理学模型促进临床前免疫肿瘤药物研发

期刊:ACS Pharmacology and Translational Science

影响因子:3.7

doi:10.1021/acsptsci.0c00178

Ma, Huilin; Pilvankar, Minu; Wang, Jun; Giragossian, Craig; Popel, Aleksander S

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

根据定量系统药理学模型预测，T细胞衔接器与PD-L1阻断剂联合治疗可增强T细胞的抗肿瘤效力。

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1136/jitc-2020-001141

Ma, Huilin; Wang, Hanwen; Sové, Richard J; Wang, Jun; Giragossian, Craig; Popel, Aleksander S

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor

应用于实体瘤的T细胞衔接器定量系统药理学模型

期刊:AAPS Journal

影响因子:3.7

doi:10.1208/s12248-020-00450-3

Ma, Huilin; Wang, Hanwen; Sove, Richard J; Jafarnejad, Mohammad; Tsai, Chia-Hung; Wang, Jun; Giragossian, Craig; Popel, Aleksander S

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

使用大鼠抗小鼠 IL-36R 单克隆抗体和 RNA 表达数据 (FANTOM5) 对抗 IL-36R 单克隆抗体 MAB92 的人体药代动力学进行基于模型的预测的回顾性分析

期刊:MAbs

影响因子:7.3

doi:10.1080/19420862.2019.1615345

Ahlberg Jennifer, Giragossian Craig, Li Hua, Myzithras Maria, Raymond Ernie, Caviness Gary, Grimaldi Christine, Brown Su-Ellen, Perez Rocio, Yang Danlin, Kroe-Barrett Rachel, Joseph David, Pamulapati Chandrasena, Coble Kelly, Ruus Peter, Woska Joseph R, Ganesan Rajkumar, Hansel Steven, Mbow M Lamine

Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics.

免疫缺陷小鼠模型在表征免疫原性抗体疗法的临床前药代动力学方面的应用

期刊:MAbs

影响因子:7.3

doi:10.1080/19420862.2016.1229721

Myzithras Maria, Bigwarfe Tammy, Li Hua, Waltz Erica, Ahlberg Jennifer, Giragossian Craig, Roberts Simon

Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings

临床前和临床环境中治疗性单克隆抗体的异速缩放

Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development

利用PBMC人源化小鼠的定量系统药理学模型促进临床前免疫肿瘤药物研发

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

根据定量系统药理学模型预测，T细胞衔接器与PD-L1阻断剂联合治疗可增强T细胞的抗肿瘤效力。

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor

应用于实体瘤的T细胞衔接器定量系统药理学模型

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

使用大鼠抗小鼠 IL-36R 单克隆抗体和 RNA 表达数据 (FANTOM5) 对抗 IL-36R 单克隆抗体 MAB92 的人体药代动力学进行基于模型的预测的回顾性分析

Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics.

免疫缺陷小鼠模型在表征免疫原性抗体疗法的临床前药代动力学方面的应用